A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice.
article
OA: closed
CC0
⤵ 7 in-corpus citations
Abstract
The inhibitory effects of a novel matrix metalloproteinase inhibitor, ONO-4817, on the development of mammary tumors and the progression of uterine adenomyosis were examined in SHN mice. First, multiparous mice which developed mammary tumors spontaneously were used. The first palpable tumor was removed, and the mice were thereafter fed chow containing ONO-4817. Any second mammary tumor developing in the other mammary fat pad was also removed, and the mice were continuously fed the chow containing ONO-4817. The mice were killed when a third tumor was detected in the other fat pad. The periods between the occurrence of the first and second tumors, and the second and third ones were significantly increased in the mice treated with ONO-4817 compared to the mice not given ONO-4817 treatment. Second, to test ONO-4817 suppression of the progression of the invasion of uterine adenomyotic tissue, mice with experimentally-induced adenomyosis were treated with ONO-4817 for 4 weeks. The degree of pathological progression of adenomyosis was less in the uteri exposed to ONO-4817 than in the uteri not exposed to the inhibitor.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (7)
- Metformin as a Potential Treatment Option for Endometriosis 2022
- Experimental Treatments of Endometriosis 2015
- An overview of early drug development for endometriosis 2015
- Methodological Issues in Preclinical Mouse Efficacy Studies of Adenomyosis 2012
- Neonatal administration of tamoxifen causes disruption of myometrial development but not adenomyosis in the C57/BL6J mouse 2010
- Emerging drugs for endometriosis 2008
- Current diagnostic and treatment strategies for adenomyosis 2006
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:12:55.732728+00:00
License: CC0
· commercial use OK